Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

388 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.
Brander D, Rizzieri D, Gockerman J, Diehl L, Shea TC, Decastro C, Moore JO, Beaven A. Brander D, et al. Among authors: diehl l. Leuk Lymphoma. 2013 Dec;54(12):2627-30. doi: 10.3109/10428194.2013.784969. Epub 2013 Apr 19. Leuk Lymphoma. 2013. PMID: 23488610 Free PMC article. Clinical Trial.
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
Advani AS, Shadman M, Ali-Osman F, Barker A, Rybicki L, Kalaycio M, Sekeres MA, de Castro CM, Diehl LF, Moore JO, Beaven A, Copelan E, Sobecks R, Talea P, Rizzieri DA. Advani AS, et al. Among authors: diehl lf. Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):473-6. doi: 10.3816/CLML.2010.n.082. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21156465 Clinical Trial.
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, DeCastro CM, Friedman DR, Diehl LF, Rehder C, Cook H, Daugherty FJ, Matta KM, Weinberg JB, Rizzieri D. Lanasa MC, et al. Leuk Lymphoma. 2012 Feb;53(2):218-24. doi: 10.3109/10428194.2011.610012. Epub 2011 Sep 23. Leuk Lymphoma. 2012. PMID: 21827374
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
Crout CA, Koh LP, Gockerman JP, Moore JO, Decastro C, Long GD, Diehl L, Gasparetto C, Niedzwiecki D, Edwards J, Prosnitz L, Horwitz M, Chute J, Morris A, Davis P, Beaven A, Chao NJ, Ali-Osman F, Rizzieri DA. Crout CA, et al. Among authors: diehl l. Cancer Invest. 2010 Jul;28(6):654-60. doi: 10.3109/07357901003631015. Cancer Invest. 2010. PMID: 20521909 Clinical Trial.
Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.
Hudson KE, Rizzieri D, Thomas SM, LeBlanc TW, Powell Z, Diehl L, Moore JO, DeCastro C, Beaven AW. Hudson KE, et al. Among authors: diehl l. Br J Haematol. 2019 Feb;184(4):647-650. doi: 10.1111/bjh.15138. Epub 2018 Feb 21. Br J Haematol. 2019. PMID: 29468651 Free PMC article. Clinical Trial. No abstract available.
388 results